Company / SG&A Expense
Korro Bio, Inc. SG&A Expense History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$30.5M
FY2025
5-year range
$14.8M / $37.2M
FY2021-FY2025
Trend
+12.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $37M to $31M over the past 3 years.
Based on SEC 10-K filings.
$31M in FY2025 with a 5-year CAGR of +15.5%.
Improved from $37M to $31M over the past 3 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -6.3%
- 5-Year CAGR
- +15.5%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +15.5%, indicating consistent growth.
- In FY2025, sg&a expense increased 12.0% year-over-year.
- Peak sg&a expense was recorded in FY2022.
- Lowest sg&a expense in the period was in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -3.49 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $30.5M | +12.0% |
| FY2024 | $27.3M | -26.6% |
| FY2022 | $37.2M | +37.1% |
| FY2021 | $27.1M | +82.8% |
| FY2020 | $14.8M | +241.9% |
| FY2019 | $4.3M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026